Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3681851 | 0.82 | MAPT (0.33) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL20918926 | 0.78 | — | — | |
| SCHEMBL19170321 | 0.78 | ALDH1A1 (0.35) | — | |
| SCHEMBL9937244 | 0.78 | KDM4E (0.32) | TSHR | |
| SCHEMBL10783613 | 0.78 | FAAH (0.35) | TSHRCHRM1 | |
| Ethylene Glycol SCHEMBL13737580 | 0.78 | PRKCA (0.37) | PRKCA | |
| Ammonia Solution, Strong SCHEMBL28278153 | 0.77 | FAAH (0.34) | TSHRCHRM1 | |
| SCHEMBL321296 | 0.75 | TSHR (0.33) | TSHR | |
| SCHEMBL826905 | 0.75 | TSHR (0.46) | TSHR | |
| SCHEMBL9937330 | 0.75 | FAAH (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1292583-A4 | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R)-4-BENZYL-2- 1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-1,4-OXAZIN-3-ONE | MERCK & CO INC (US) | 2004-02-25 | — | — | EP | disclosed |
| EP-1292583-A1 | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R)-4-BENZYL-2- 1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-1,4-OXAZIN-3-ONE | Merck & Co., Inc. (US) | 2003-03-19 | — | — | EP | disclosed |
| US-6469164-B2 | 2-HYDROXY GROUP OF 4-BENZYL-2-HYDROXY-1,4-OXAZIN-3-ONE IS ACTIVATED WITH 1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL) ETHAN-1-OL IN PRESENCE OF LEWIS ACID, CRYSTALLIZATION OF DRIVEN EPIMERIZATION OF ANOMERIC CENTER WITH A BASE | MERCK & CO., INC. | 2002-10-22 | — | — | US | disclosed |
| US-20020052493-A1 | Process for the synthesis of (2R, 2-alpha-R) -4-benzyl-2-[1- (3,5-bis (trifluoromethyl) phenyl) ethoxy] -1,4-oxazine-3-one | MERCK SHARP & DOHME CORP. | 2002-05-02 | — | — | US | disclosed |
| WO-2001094323-A1 | PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R)-4-BENZYL-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY]-1,4-OXAZIN-3-ONE | MERCK & CO., INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052493-A1 | Process for the synthesis of (2R, 2-alpha-R) -4-benzyl-2-[1- (3,5-bis (trifluoromethyl) phenyl) ethoxy] -1,4-oxazine-3-one | CYP4B1, CBR1, CYP4Z1 | PRKCA 2785/4885TSHR 562/4885CHRM2 1355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.